发明授权
US08409580B2 Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
有权
针对P-糖蛋白170的治疗性疫苗用于抑制癌症治疗中的多药耐药性
- 专利标题： Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
- 专利标题（中）： 针对P-糖蛋白170的治疗性疫苗用于抑制癌症治疗中的多药耐药性
-
申请号： US12870893申请日： 2010-08-30
-
公开(公告)号： US08409580B2公开(公告)日： 2013-04-02
- 发明人: Pierre-Francois Tosi , Claudie Madoulet , Claude Nicolau , David T. Hickman
- 申请人： Pierre-Francois Tosi , Claudie Madoulet , Claude Nicolau , David T. Hickman
- 申请人地址： CH Lausanne
- 专利权人： AC Immune SA
- 当前专利权人： AC Immune SA
- 当前专利权人地址： CH Lausanne
- 代理机构： Agris & von Natzmer LLP
- 代理商 Joyce von Natzmer
- 优先权： FR0309188 20030725
- 主分类号： A61K39/00
- IPC分类号： A61K39/00 ; A61K39/385 ; A61K38/00 ; A61K38/04 ; A61K38/10 ; C07K7/00
摘要：
The invention relates to an immunogenic composition which comprises, firstly, a carrier and, secondly, as antigenic structure, conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein, each peptide being combined with several molecules of fatty acid containing a carbon chain of between C12 and C24 so as to allow, under suitable administration conditions, the induction of anti-P-170 antibodies.The invention relates to said composition for defining means for treating multidrug resistances.
公开/授权文献
信息查询
